JOURNEY MEDICAL CORP (DERM) Stock Price, Forecast & Analysis
NASDAQ:DERM • US48115J1097
DERM Key Statistics, Chart & Performance
The current stock price of DERM is 8.17 USD. In the past month the price decreased by -3.31%. In the past year, price increased by 45.12%.
DERM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DERM. When comparing the yearly performance of all stocks, DERM is one of the better performing stocks in the market, outperforming 80.71% of all stocks.
DERM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DERM. Both the profitability and financial health of DERM have multiple concerns.
DERM Financial Highlights
Over the last trailing twelve months DERM reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 41.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.17% | ||
| ROE | -33.45% | ||
| Debt/Equity | 0.75 |
DERM Forecast & Estimates
10 analysts have analysed DERM and the average price target is 13.77 USD. This implies a price increase of 68.54% is expected in the next year compared to the current price of 8.17.
For the next year, analysts expect an EPS growth of 52% and a revenue growth 13.98% for DERM
DERM Ownership
DERM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DERM
Company Profile
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Company Info
JOURNEY MEDICAL CORP
9237 E Via De Ventura Blvd., Suite 105, Suite 105
Scottsdale ARIZONA 94025 US
CEO: Thomas G. Wiggans
Employees: 41
Phone: 14804346670
JOURNEY MEDICAL CORP / DERM FAQ
What does JOURNEY MEDICAL CORP do?
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Can you provide the latest stock price for JOURNEY MEDICAL CORP?
The current stock price of DERM is 8.17 USD. The price decreased by -6.2% in the last trading session.
Does DERM stock pay dividends?
DERM does not pay a dividend.
How is the ChartMill rating for JOURNEY MEDICAL CORP?
DERM has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for JOURNEY MEDICAL CORP?
JOURNEY MEDICAL CORP (DERM) has a market capitalization of 222.71M USD. This makes DERM a Micro Cap stock.
What is the ownership structure of JOURNEY MEDICAL CORP (DERM)?
You can find the ownership structure of JOURNEY MEDICAL CORP (DERM) on the Ownership tab.
Can you provide the short interest for DERM stock?
The outstanding short interest for JOURNEY MEDICAL CORP (DERM) is 12.55% of its float.